Genetic alterations of WWOX in Wilms' tumor are involved in its carcinogenesis

Oncology Reports

Volumn 28, Issue 4, 2012, Pages 1417-1422

  Płuciennik, Elzbieta ^a   Nowakowska, Magdalena ^a   Wujcicka, Wioletta I ^a   Sitkiewicz, Anna ^a   Kazanowska, Bernarda ^b   Zielínska, Elzbieta ^a   Bednarek, Andrzej K ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Wilms' tumor; WWOX gene

Indexed keywords

CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; KI 67 ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; UVOMORULIN;

APOPTOSIS; ARTICLE; BAX GENE; CARCINOGENESIS; CCND1 GENE; CCNE1 GENE; CDH1 GENE; CELL ADHESION; CELL CYCLE REGULATION; CELL PROLIFERATION; CHILD; CLINICAL ARTICLE; DNA METHYLATION; EGFR GENE; ERBB4 GENE; FEMALE; GENE; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; INFANT; INTRON; KI67 GENE; MALE; NEPHROBLASTOMA; ONCOGENE NEU; PRIORITY JOURNAL; PROMOTER REGION; PROTO ONCOGENE; REAL TIME POLYMERASE CHAIN REACTION; SCHOOL CHILD; SIGNAL TRANSDUCTION; TP73 GENE; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; WWOX GENE;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL PROLIFERATION; CHILD; CHILD, PRESCHOOL; CYCLIN D1; CYCLIN E; DNA METHYLATION; EXONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; KI-67 ANTIGEN; KIDNEY NEOPLASMS; LOSS OF HETEROZYGOSITY; ONCOGENE PROTEINS; OXIDOREDUCTASES; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS; WILMS TUMOR;

EID: 84866443226     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1940     Document Type: Article

References (34)

1. Green DM, D'Angio GJ, Beckwith JB, Breslow NE, Grundy PE, Ritchey ML and Thomas PR: Wilms tumor. CA Cancer J Clin 461: 46-63, 1996.
2. Li W, Kessler P, Yeger H, Alami J, Reeve AE, Heathcott R, Skeen J and Williams BR: A gene expression signature for relapse of primary wilms tumors. Cancer Res 65: 2592-2601, 2005.
3. Grundy PE, Telzerow PE, Breslow N, Moksness J, Huff V and Paterson MC: Loss of heterozygosity for chromosomes 16q and 1p in wilms' tumors predicts an adverse outcome. Cancer Res 54: 2331-2333, 1994.
4. Grundy PE, Breslow NE, Li S, Perlman E, Beckwith JB, Ritchey ML, Shamberger R C, et al: Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology wilms tumor: a report from the national wilms tumor study group. J Clin Oncol 23: 7312-7321, 2005.
5. Messahel B, Williams R, Ridolfi A, A'hern R, Warren W, Tinworth L, Hobson R, et al: Allele loss at 16q defines poorer prognosis wilms tumour irrespective of treatment approach in the UKW1-3 clinical trials: a children's cancer and leukaemia group (CCLG) study. Eur J Cancer 45: 819-826, 2009.
6. Bednarek AK, Laflin KJ, Daniel RL, Liao Q, Hawkins KA and Aldaz CM: WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer. Cancer Res 60: 2140-2145, 2000.
7. Aqeilan RI, Donati V, Palamarchuk A, Trapasso F, Kaou M, Pekarsky Y, Sudol M and Croce CM: WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function. Cancer Res 65: 6764-6772, 2005.
8. Aqeilan RI, Donati V, Gaudio E, Nicoloso MS, Sundvall M, Korhonen A, Lundin J, et al: Association of Wwox with ErbB4 in breast cancer. Cancer Res 67: 9330-9336, 2007.
9. Aqeilan RI, Pekarsky Y, Herrero JJ, Palamarchuk A, Letofsky J, Druck T, Trapasso F, et al: Functional association between Wwox tumor suppressor protein and P73, a P53 homolog. Proc Natl Acad Sci USA 101: 4401-4406, 2004.
10. Aqeilan RI, Palamarchuk A, Weigel RJ, Herrero JJ, Pekarsky Y and Croce CM: Physical and functional interactions between the Wwox tumor suppressor protein and the AP-2gamma transcription factor. Cancer Res 64: 8256-8261, 2004.
11. Guler G, Huebner K, Himmetoglu C, Jimenez RE, Costinean S, Volinia S, Pilarski RT, et al: Fragile histidine triadprotein, WW domain-containing oxidoreductase protein Wwox, and activator protein 2gamma expression levels correlate with basal phenotype in breast cancer. Cancer 115: 899-908, 2009.
12. Gaudio E, Palamarchuk A, Palumbo T, Trapasso F, Pekarsky Y, Croce CM and Aqeilan RI: Physical association with WWOX suppresses C-Jun transcriptional activity. Cancer Res 66: 11585-11589, 2006.
13. Aqeilan RI, Hassan MQ, de Bruin A, Hagan JP, Volinia S, Palumbo T, Hussain S, et al: The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism. J Biol Chem 283: 21629-21639, 2008.
14. Aqeilan RI, Trapasso F, Hussain S, Costinean S, Marshall D, Pekarsky Y, Hagan JP, et al: Targeted deletion of Wwox reveals a tumor suppressor function. Proc Natl Acad Sci USA 104: 3949-3954, 2007.
15. Maeda N, Semba S, Nakayama S, Yanagihara K and Yokozaki H: Loss of WW domain-containing oxidoreductase expression in the progression and development of gastric carcinoma: clinical and histopathologic correlations. Virchows Arch 457: 423-432, 2010.
16. Aqeilan RI, KurokiT, Pekarsky Y, Albagha O, Trapass F, Baffa R, Huebner K, et al: Loss of WWOX expression in gastric carcinoma. Clin Cancer Res 10: 3053-3058, 2004.
17. Kuroki T, Trapasso F, Shiraishi T, Alder H, Mimori K, Mori M and Croce CM: Genetic alterations of the tumor suppressor gene WWOX in esophageal squamous cell carcinoma. Cancer Res 62: 2258-2260, 2002.
18. Kuroki T, Yendamuri S, Trapasso F, Matsuyama A, Aqeilan RI, Alder H, Rattan S, et al: The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res 10: 2459-2465, 2004.
19. Yendamuri S, Kuroki T, Trapasso F, Henry AC, Dumon KR, Huebner K, Williams NN, et al: WW domain containing oxidoreductase gene expression is altered in non-small cell lung cancer. Cancer Res 63: 878-881, 2003.
20. Chen T, Sahin A and Aldaz CM: Deletion map of chromosome 16q inductalcarcinoma in situ of the breast: refining a putative tumor suppressor gene region. Cancer Res 56: 5605-5609, 1996.
21. Iliopoulos D, Guler G, Han SY, Johnston D, Druck T, McCorkell KA, PalazzoJ, et al: Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer. Oncogene 24: 1625-1633, 2005.
22. Ishii H, Vecchione A, Furukawa Y, Sutheesophon K, Han SY, Druck T, Kuroki T, et al: Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies. Mol Cancer Res 1: 940-947, 2003.
23. Vujanic GM, Sandstedt B, Harms D, Kelsey A, Leuschner I and de Kraker J: Revised international society of paediatric oncology (SIOP) working classification of renal tumors of childhood. Med Pediatr Oncol 38: 79-82, 2002.
24. Holemon H, Korshunova Y, Ordway JM, Bedell JA, Citek RW, Lakey N, Leon J, et al: MethylScreen: DNA methylation density monitoringusing quantitative PCR. Biotechniques 43: 683-693, 2007.
25. Skotnicka-Klonowicz G, Rieske P, Bartkowiak J, Szymik-Kantorowicz S, Daszkiewicz P and Debiec-Rychter M: 16q heterozygosity loss in Wilms' tumour in children and its clinical importance. Eur J Surg Oncol 26: 61-66, 2000.
26. Feinberg AP: Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: an introduction. Cancer Res 59: S1743-S1746, 1999.
27. Loeb DM, Korz D, Katsnelson M, Burwell EA, Friedman AD and Sukumar S: Cyclin E is a target of WT1 transcriptional repression. J Biol Chem 277: 19627-19632, 2002.
28. Berrebi D, Leclerc J, Schleiermacher G, Zaccaria I, Boccon-Gibod L, Fabre M, Jaubert F, et al: High cyclin E staining index in blastemal, stromal or epithelial cells is correlated with tumor aggressiveness in patients with nephroblastoma. PLoS One 3: e2216, 2008.
29. Faussillon M, Monnier L, Junien C and Jeanpierre C: Frequent overexpression of cyclin D2/cyclin-dependent kinase 4 in Wilms' tumor. Cancer Lett 221: 67-75, 2005.
30. Scharnhorst V, Dekker P, van der Eb AJ and Jochemsen AG: Physical interaction between wilms tumor 1 and P73 proteins modulates their functions. J Biol Chem 275: 10202-10211, 2000.
31. Ghanem MA, van der Kwast TH, Den Hollander JC, Sudaryo MK, van den Heuvel MM, Noordzij MA, Nijman RJ, et al: The prognostic significance of apoptosis-associated proteins BCL-2, BAX and BCL-X in clinical nephroblastoma. Br J Cancer 85: 1557-1563, 2001.
32. Tanaka K, Granata C, Wang Y, O'Briain DS and Puri P: Apoptosis and Bcl-2 oncogene expression in wilms' tumor. Pediatr Surg Int 15: 243-247, 1999.
33. Wetli,SC, Leuschner I, Harms D, Rufle A, Foerster A, Bihl M, Graf N, et al: KIT, PDGFRalpha and EGFR analysis in nephroblastoma. Virchows Arch 452: 637-650, 2008.
34. Vasei M, Modjtahedi H, Ale-Booyeh O, Mosallaei A, Kajbafzadeh AM, Shahriari M, Ghaderi AA, et al: Amplification and expression of EGFR and ERBB2 in Wilms' tumor. Cancer Genet Cytogenet 194: 88-95, 2009.